ITT0921
ITT0921
- Catalog: ITT0921
- Gene/Protein: CHST6
- Product Description: Immunotag™ CHST6 Polyclonal Antibody
385.0000
Price in reward points: 385
| Antibody Specification | |
| Datasheet | 
|
| Target Protein | CHST6 |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | IF,ELISA |
| Recommended Dilution | Immunofluorescence: 1/200 - 1/1000. ELISA: 1/20000. Not yet tested in other applications. |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Rabbit |
| Immunogen | The antiserum was produced against synthesized peptide derived from human CHST6. AA range:331-380 |
| Specificity | CHST6 Polyclonal Antibody detects endogenous levels of CHST6 protein. |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen |
| Form | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Gene Name | CHST6 |
| Accession No. | Q9GZX3 |
| Alternate Names | CHST6; Carbohydrate sulfotransferase 6; Corneal N-acetylglucosamine-6-O-sulfotransferase; C-GlcNAc6ST; hCGn6ST; Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 4-beta; GST4-beta; N-acetylglucosamine 6-O-sulfotransfera |
| Description | carbohydrate sulfotransferase 6(CHST6) Homo sapiens The protein encoded by this gene is an enzyme that catalyzes the transfer of a sulfate group to the GlcNAc residues of keratan. Keratan sulfate helps maintain corneal transparency. Defects in this gene are a cause of macular corneal dystrophy (MCD). [provided by RefSeq, Jan 2010], |
| Cell Pathway/ Category | Keratan sulfate biosynthesis, |
| Protein Expression | Lung, |
| Subcellular Localization | Golgi membrane,Golgi apparatus,integral component of membrane, |
| Protein Function | caution:PubMed:12824236 reported a Gly-204 variant, however according to their results reported in figure 1, it is a Gln-204 variant.,disease:Defects in CHST6 are the cause of macular corneal dystrophy (MCD) [MIM:217800]. MCD is an autosomal recessive disease characterized by corneal opacities. Onset occurs in the first decade, usually between ages 5 and 9. The disorder is progressive. Minute, gray, punctate opacities develop. Corneal sensitivity is usually reduced. Painful attacks with photophobia, foreign body sensations, and recurrent erosions occur in most patients. There are different types of MCD: MCD type I, in which there is a virtual absence of sulfated keratan sulfate (KS) in the serum and cornea, as determined by KS-specific antibodies; and MCD type II, in which the normal sulfated KS-antibody response is present in cornea and serum. MCD type I patients usually have a homozygous missense mutation, while MCD type II patients show a large deletion and replacement in the upstream region of CHST6. The only missense mutation for type II is Cys-50, which is heterozygous with a replacement in the upstream region on the other allele of CHST6.,function:Catalyzes the transfer of sulfate to position 6 of non-reducing N-acetylglucosamine (GlcNAc) residues of keratan. Mediates sulfation of keratan in cornea. Keratan sulfate plays a central role in maintaining corneal transparency. Acts on the non-reducing terminal GlcNAc of short and long carbohydrate substrates that have poly-N-acetyllactosamine structures.,online information:GlycoGene database,similarity:Belongs to the sulfotransferase 1 family. Gal/GlcNAc/GalNAc subfamily.,tissue specificity:Expressed in cornea. Mainly expressed in brain. Also expressed in spinal cord and trachea., |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |
| Material Safety Data Sheet | |
| English_US |
|
| Danish |
|
| Dutch |
|
| English_UK |
|
| French |
|
| German |
|
| Spanish |
|
| Norwegian |
|
| Portuguese |
|
| Finnish |
|
| Swedish |
|
| Polish |
|